Differences

This shows you the differences between two versions of the page.

--- pharmaceutical_companies:pfizer [2022/07/15 18:19]
pamela [History of Pfizer]
+++ pharmaceutical_companies:pfizer [2023/01/10 17:37] (current)
liam [Payments to Individuals]
@@ Line 330: / Line 330: @@
  Importantly, BNT162b2 induced potent SARS-CoV-2 neutralizing antibodies in vaccinated-macaques, and viral antigen-specific CD4+ and CD8+ T cells. Rhesus macaques (2-4-year-old males) were immunized by intramuscular (IM) immunization with 30 µg or 100 µg of BNT162b2 or saline control on Days 0 and 21 (2 doses). After two immunizations, neutralization titers were detectable in rhesus macaques sera with geometric mean titers of 962 (on Day 35 for the 30 µg group) or 1,689 (on Day 28 for the 100 µg group). Neutralizing antibody titers persisted to at least day 56, with higher geometric mean titers (GMTs) than those in a panel of human convalescent sera. BNT162b2 vaccination elicited a high frequency of CD4+ T cells that produced IFN-ɣ, IL-2, and TNF-α, and almost no IL-4 producing CD4+ cells were detectable, indicating a TH1-biased response, which is an immune profile thought to promote vaccine safety. BNT162b2 also elicited spike-specific IFN-ɣ producing CD8+ T cell responses, which is thought to promote an anti-viral effect.
-In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, 1, or 5 µg) generated B-cell and T-cell immune responses in BALB/c mice, and SARS-CoV-2 pseudovirus neutralizing activity increased steadily to Day 28, the last day for which titers are reported. CD4+ and CD8+ T-cells from splenocytes isolated from BNT162b2-immunized mice were strongly positive for IFNγ and IL-2, producing high levels of the TH1 cytokines but minute amounts of TH2 cytokines, suggesting a robust, TH1-biased T cell adaptive immune response.
+In a preclinical murine model, a single IM immunization of BNT162b2 (0.2, 1, or 5 µg) generated B-cell and T-cell immune responses in BALB/c mice, and SARS-CoV-2 pseudovirus neutralizing activity increased steadily to Day 28, the last day for which titers are reported. CD4+ and CD8+ T-cells from splenocytes isolated from BNT162b2-immunized mice were strongly positive for IFNγ and IL-2, producing high levels of the TH1 cytokines but minute amounts of [[:TH2]] cytokines, suggesting a robust, TH1-biased T cell adaptive immune response.
 Many of these preclinical data and the Phase 1 clinical results contributed to the decision by Pfizer and BioNTech to commence the global (except for China) Phase 2/3 safety and efficacy portion of the clinical study to evaluate potential prevention of COVID-19 disease by BNT162b2. The Phase 2/3 study has enrolled over 25,000 participants 18 to 85 years of age in the U.S., Argentina and Brazil. Additional enrollment is planned in Germany, Turkey and South Africa. The study is an event-driven trial.((https://web.archive.org/web/20200918085932/https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-data-preclinical-studies-mrna))
@@ Line 356: / Line 356: @@
 | [[:Dawn Bowdish]]  | Research Award  | Unknown  | Funds for pneumonia research from [[:Ontario Lung Association]] and [[Pfizer]], and ASPIRE-Pfizer New Investigator Award.((Bowdish, D. M. E. (2013, February 11). //Dr. Dawn Bowdish receives a research award from the Ontario Lung Association and Pfizer Canada (and gets to attend a swanky event to receive it!).// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/AQqx1)) ((Bowdish, D. M. E. (2011, July 3). //Dawn wins ASPIRE-Pfizer New Investigator Award.// Bowdish Lab. Retrieved December 1, 2021, from https://archive.ph/Dvre1))  |
 | [[:Richard Choi]]  | Speakers Bureau/Honoraria/Consulting  | Unknown  | Disclosed during CardioVascUpdate presentation.((Verma, S., Bucci, C., Choi, R., & Gupta, A. (2020, June 12). //Navigating Vascular Protective Strategies in HighRisk Patients During the Current Era: Practical Applications.// CardioVascUpdate. https://web.archive.org/web/20210304170904/https://cardiovascupdate.ca/files/2020/CV%20Update%20Symposium-Presentation.pdf))  |
+| [[:Nigel Crawford]]  | Research  | Unknown  | "Investigator on a number of epidemiological surveillance research and vaccine safety research. Funds received by employer", [[:Murdoch Children's Research Institute]] (MCRI).((//Australian Technical Advisory Group on Immunisation - Conflict of Interest.// Australia Government Department of Health and Aged Care. Retrieved October 24, 2022, from https://web.archive.org/web/20221024032912/https://www.health.gov.au/sites/default/files/atagi-conflict-of-interest-disclosures.pdf))  |
 | [[:David Fisman]]  | Honorarium  | Unknown  | Honorarium paid for advisory board meetings regarding COVID-19 related projects.((Fisman, D. (2021). //Declaration of Interest.// Ontario COVID-19 Science Advisory Table. https://covid19-sciencetable.ca/wp-content/uploads/2020/10/Declaration-of-Interest_Science-Table_David-Fisman2.pdf))  |
 | [[:Soren Gantt]]  | Grant  | Unknown  | Research grant paid to Gantt.((Lebatteux, D., Soudeyns, H., Boucoiran, I., Gantt, S., & Diallo, A. B. (2022). //Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures.// bioRxiv. Preprint. https://doi.org/10.1101/2022.02.07.479343))  |
@@ Line 600: / Line 601: @@
 ==== Allegations of Funding Terrorism ====
 There is currently a lawsuit against Pfizer over claims of funding terrorism in Iraq.((January 5, 2022 | Inquirer.net | [[https://newsinfo.inquirer.net/1536247/us-court-revives-lawsuit-against-pfizer-others-on-iraq-terrorism-funding-claims|US court revives lawsuit against Pfizer, others on Iraq terrorism funding claims]]))
+==== Academic Partners UCSF ====
+May 29, 2013
+Pfizer’s Centers for Therapeutic Innovation Partners with UCSF to Expand Drug Discovery Capabilities
+UCSF Becomes First Partner in Both Small-Molecule and Biologics Discovery
+By Kristen Bole {{ :pharmaceutical_companies:pfizer_2013_ucsf.png?400|}}
+Pfizer has announced the expansion of its [[:Centers for Therapeutic Innovation]] (CTI) into the development of small-molecule drug candidates through a partnership with UC San Francisco.
+This partnership provides investigators from UCSF with access to Pfizer’s industry-leading small-molecule drug development capabilities, working side-by-side with Pfizer scientists with the goal of jointly translating promising basic research into drug candidates that have the potential to bring innovative new therapies to patients.
+“This expansion is part of the natural evolution of CTI as we continue to drive forward the next generation of innovative, differentiated medicines. With Pfizer’s strong heritage in medicinal chemistry, it makes perfect sense to expand CTI’s mandate to include small-molecule projects,” said Jose Carlos Gutierrez-Ramos, PhD, group senior vice president and head of biotherapeutics R&D at Pfizer. “UCSF has been a great collaborator and has an established history in this area. I am confident that together we are better positioned to deliver faster and more efficient drug discovery with the aim of bringing new medicines to patients more quickly.
+The collaboration builds upon an October 2010 agreement between CTI and UCSF in large-molecule – also called biologics – discovery, with both agreements aiming to accelerate the translation of biomedical research into new medications and therapies. ((https://web.archive.org/web/20210630074451/https://www.ucsf.edu/news/2013/05/106276/pfizers-centers-therapeutic-innovation-partners-ucsf-expand-drug-discovery))
+==== Pfizer Recommends Hydroxychloroquine for Covid-19 ====
+{{ :pharmaceutical_companies:pfizer_hcq_treats_covid_-_mechanism_page.png?600|}}
+See Ashmedai article at Substack or [[:Hydroxychloroquine]] in wiki. ((https://ashmedai.substack.com/p/pfizer-still-recommends-hydroxychloroquine))
+TO give some added perspective, the FDA’s evidence that HCQ does NOT work is EXCLUSIVELY regarding hospitalized covid patients - precisely the same folks for which Pfizer is recommending HCQ!!
+Pfizer is so transcendently theophanic that its pronouncements are the embodiment of the scientific method, as we all witnessed when the CDC Director herself understood that a CNN report of Pfizer’s proclamation of its vaccine trial’s results amounted to an official communique of eternally settled Scientific fact.
+{{ :pharmaceutical_companies:pfizer_hcq_treats_covid_text_box_large.png?400|}}
+If Pfizer declares that HCQ works to treat covid - we can limit their revised catechism to late stage severe covid if you really want to be nitpicky here - then doesn’t this mean that the formerly heretical position that HCQ can treat covid is now fundamental doctrinal truth??
+Alternatively, if we can’t trust Pfizer, the oracle of science, who can we trust????
+Pfizer pdf Wayback((https://web.archive.org/web/20221213102408/https://pfizermedical.pfizerpro.com/api/vc/en/medical/assets/343db662-0565-4062-8956-00ddd5bb4fbb/COVID-19%20Antiviral%20-%202.%20Clinical%20Presentation-Proactive.pdf))